Can glucagon like peptide 1 (GLP1) agonists or sodium-glucose co-transporter 2 (SGLT2) inhibitors ameliorate non-alcoholic steatohepatitis in people with or without diabetes?

Current Vascular Pharmacology

Volumn 14, Issue 6, 2016, Pages 494-497

  Athyros, Vasilios G ^a   Katsiki, Niki ^a   Karagiannis, Asterios ^a  

^a ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALOGLIPTIN; ALPHA TOCOPHEROL; ATORVASTATIN; CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; IPRAGLIFLOZIN; LIRAGLUTIDE; LIVER ENZYME; PIOGLITAZONE; ROSUVASTATIN; SEMAGLUTIDE; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

DIABETES MELLITUS; EDITORIAL; HUMAN; INFLAMMATION; LIVER FIBROSIS; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC FATTY LIVER DISEASE ACTIVITY SCORE; NONHUMAN; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; AGONISTS; ANTAGONISTS AND INHIBITORS; BLOOD; COMPARATIVE STUDY;

DIABETES MELLITUS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; NON-ALCOHOLIC FATTY LIVER DISEASE; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84995632414     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/1570161114666160909161811     Document Type: Editorial

References (33)

1. Athyros VG, Tziomalos K, Katsiki N, et al. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. World J Gastroenterol 2015; 21: 6820-34.
2. Doycheva I, Patel N, Peterson M, Loomba R. Prognostic implication of liver histology in patients with nonalcoholic fatty liver disease in diabetes. J Diabetes Complications 2013; 27: 293-300.
3. Nascimbeni F, Pais R, Bellentani S, et al. From NAFLD in clinical practice to answers from guidelines. J Hepatol 2013; 59: 859-71.
4. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. European Association for the Study of the Liver (EASL). Electronic address: easloffice@easloffice.eu; European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). J Hepatol 2016 Mar 10. pii: S0168-8278 (15) 00734-5
5. Sanyal AJ, Mofrad PS, Contos MJ, et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clinical Gastroenterology and Hepatology 2004; 2: 1107-15.
6. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006; 355: 2297-307.
7. Aithal GP, Thomas JA, Kaye PV, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008; 135: 1176-84.
8. Sanyal AJ, Chalasani N, Kowdley KV, et al, NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362: 1675-85.
9. Mashitani T, Noguchi R, Okura Y, et al. Efficacy of alogliptin in preventing non-alcoholic fatty liver disease progression in patients with type 2 diabetes. Biomed Rep 2016; 4: 183-7.
10. Yilmaz Y, Yonal O, Deyneli O, et al. Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis. Acta Gastroenterol Belg 2012; 75: 240-4.
11. Shao N, Kuang HY, Hao M, et al. Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes. Diabetes Metab Res Rev 2014; 30: 521-9.
12. Kenny PR, Brady DE, Torres DM, et al. Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: a case series. Am J Gastroenterol 2010; 105: 2707-9.
13. Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, doubleblind, randomised, placebo-controlled phase 2 study. Lancet 2016; 387: 679-90.
14. Kim D, Kim WR, Kim HJ, Therneau TM. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 2013; 57: 1357-65.
15. Komiya C, Tsuchiya K, Shiba K, et al. Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction. PLoS One 2016; 11: e0151511.
16. Honda Y, Imajo K, Kato T, et al. The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice. PLoS One 2016; 11: e0146337.
17. Hayashizaki-Someya Y, Kurosaki E, Takasu T, et al. Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats. Eur J Pharmacol 2015; 754: 19-24.
18. Suzuki M, Takeda M, Kito A, et al. Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models. Nutr Diabetes. 2014; 4: e125.
19. Nakano S, Katsuno K, Isaji M, et al. Remogliflozin Etabonate Improves Fatty Liver Disease in Diet-Induced Obese Male Mice. J Clin Exp Hepatol 2015; 5: 190-8.
20. Ferrannini E, Baldi S, Frascerra S, et al. Shift to fatty substrates utilization in response to sodium-glucose co-transporter-2 inhibition in nondiabetic subjects and type 2 diabetic patients. Diabetes 2016; 65 (5): 1190-5.
21. Zinman B, Wanner C, Lachin JM, et al; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373: 2117-28.
22. Stavropoulos K, Imprialos KP, Boutari C, et al. Canagliflozin and Hypertension: Is It the Optimal Choice for All Hypertensive Patients? J Clin Hypertens (Greenwich) 2016 Apr 21 [Epub ahead of print].
23. Song P, Onishi A, Koepsell H, Vallon V. Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus. Expert Opin Ther Targets 2016 Apr 12: 1-17. [Epub ahead of print].
24. Valbusa F, Bonapace S, Grillo C, et al. Nonalcoholic Fatty Liver Disease Is Associated With Higher 1-year All-Cause Rehospitalization Rates in Patients Admitted for Acute Heart Failure. Medicine (Baltimore) 2016; 95: e2760.
25. Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol 2015; 62: S47-64.
26. Hartman I, Rojas E, Rodríguez-Molina D. Incretin-based therapy for type 2 diabetes mellitus: pancreatic and extrapancreatic effects. Am J Ther 2013; 20: 384-93.
27. Seufert J. SGLT2 inhibitors-an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin. Diabetes Metab Syndr Obes 2015; 8: 543-54.
28. Kargiotis K, Athyros VG, Giouleme O, et al. Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. World J Gastroenterol 2015; 21: 7860-8.
29. Kargiotis K, Katsiki N, Athyros VG, et al. Effect of rosuvastatin on non-alcoholic steatohepatitis in patients with metabolic syndrome and hypercholesterolaemia: a preliminary report. Curr Vasc Pharmacol 2014; 12: 505-11.
30. Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010; 376: 1916-22.
31. Athyros VG, Giouleme O, Ganotakis ES, et al. Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study. Arch Med Sci 2011; 7: 796-805.
32. Tikkanen MJ, Fayyad R, Faergeman O, et al. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels. Int J Cardiol 2013; 168: 3846-52.
33. Dongiovanni P, Petta S, Mannisto V, et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J Hepatol 2015; 63: 705-12.